Abstract Although headaches have recognized impact, there are no public policies in Brazil addressing this problem. The Brazilian Headache Society and the Brazilian Association of Cluster Headache and Migraine promoted a summit to discuss Public Policy and Advocacy for headache disorders. Professionals from various segments, representing various sectors of society, gathered in April 2019 in Brasília, defining the most important points for achieving advances in public policies in headache in Brazil, such as: inclusion in the chronic diseases surveillance agenda; improving public understanding and access to diagnosis and treatment; teaching in colleges and medical residences, structuring care networks, intervention models, clinical protocols and legislation supporting public policies in headache.

We report herein a rare instance in which a patient presented with a hemorrhagic cerebral metastasis as the initial manifestation of a hepatocellular carcinoma (HCC). A few cases of cerebral metastasis from HCC have been reported in the literature, mainly from eastern countries. This is the first report from South America of a cerebral metastasis from hepatocellular carcinoma.

BACKGROUND AND OBJECTIVE: Obesity is a major public health problem worldwide. Little is known about the prevalence and impact of headache disorders in obese patients. The objective of this study was to assess the prevalence of primary headaches in obese patients and controls. METHOD: Seventy-four consecutive obese patients from the obesity surgery service were studied, and compared to controls with body mass index less than 25. RESULTS: Fifty-six patients (75%) had a headache diagnosis, 49 migraine (66%), 7 tension-type headache (9%), 36 (48%) had incapacitating headaches. CONCLUSION: Primary headaches are more common and incapacitating in obese patients than controls, migraine is the most important diagnosis in this population. Headaches should be properly diagnosed and treated in obese patients.

ABSTRACT Objective Headache and rhinitis are highly prevalent and comorbid. The objective of the present study is to analyze the correlation of headache and rhinitis, in addition to the temporal pattern of these diseases in 17 years, using the Google Trends platform. Methods Google Trends was searched from January 2004 to June 2021, using the entry: [“rinite” (rhinitis) + “dor de cabeça” (headache)” + “Alzheimer” + “enxaqueca” (migraine)]. Migraine, primary headache, and Alzheimer’s, with no clear relation with headache, were used as controls. After the descriptive analysis by dispersion diagrams, Pearson’s test and a simple regression model were performed. Subsequently, this study analyzed the seasonality of the volume of research on rhinitis and headache. Results A strong correlation between rhinitis and headache (0.86) was found in the time interval analyzed. In addition, a seasonality was identified in the volume of searches for the term rhinitis with increased volume in the fall and peaks in the month of May, with a decrease in the spring and early summer. Moreover, an increase of searches on headache was observed, suggesting worse burden of this pathology. Conclusion Headaches and rhinitis were correlated in 17 years of research on the Google Trends platform. Circannual variation of both conditions was observed. Additional studies with digital research may be useful to better understand the epidemiology and comorbidities of headache.

São relatados dois casos da síndrome da cefaléia em salvas - nevralgia do trigêmeo. O primeiro caso, um paciente que apresentava crises do tipo trigeminal, do lado direito da face, acompanhadas de sinais autonômicos homolaterais do tipo lacrimejamento, coriza, congestão ocular, ptose palpebral parcial. As crises eram espontâneas ou desencadeadas por estímulos em "zonas de gatilho", com duração de segundos e numerosas ocorrências durante o dia. A periodicidade dos surtos era de aproximadamente 6 meses. Houve alivio dos sintomas quando da utilização de carbamazepina, na dose de 800 mg por dia. No segundo caso, o paciente apresentava dor excruciante, do tipo nevrálgico, do lado esquerdo da face, acompanhada de lacrimejamento, conjestão ocular, ptose palpebral parcial, rinorréia, fotofobia e fonofobia. A periodicidade dos surtos era de aproximadamente 12 meses. O exame neurológico revelou "zonas de gatilho" na primeira e segunda divisões do nervo trigêmeo. O paciente foi tratado com verapamil (160 mg/dia) e prednisona (60 mg/dia), com melhora da dor. A revisão da literatura mostrou o relato de 37 casos, divididos em dois grupos de pacientes. No primeiro grupo, os pacientes apresentavam surtos de cefaléia em salvas e nevralgia do trigêmeo ocorrendo em tempos diferentes. No segundo grupo, com apenas 9 casos, os quadros clínicos se sobrepõem do ponto de vista temporal, à semelhança dos casos aqui apresentados.

INTRODUCTION: Chronic migraine (CM) is a common medical condition affecting 2.4% of the general population. Depression is one of the most frequent comorbid disorders in CM. METHOD: Seventy patients diagnosed with chronic migraine were studied. All patients evaluated filled out the Beck Depression Inventory (BDI). Depression severity was divided into none or minimal depression, mild, moderate, and severe. RESULTS: BDI ranged from 4 to 55, mean 21 ± 10.7. Moderate or severe depression, were present in 58.7% of the patients . Some degree of depression appeared in 85.8% of patients. The BDI scores correlated with pain intensity (p = 0.02). Severe depression was more frequent in patients with comorbid fibromyalgia and in patients reporting fatigue. CONCLUSION: The BDI is an easy tool to access depression in CM patients. Suicide risk assessment is needed in CM patients. Patients with fibromyalgia and fatigue are at even higher risk for severe depression.

ABSTRACT Objective To describe the evolution of 15 patients who were treated for difficult-to-control episodic and chronic cluster headaches with clomiphene. Methods Clomiphene treatment was used for seven chronic and eight episodic cluster headache patients. The chronic patients were refractory to the medication being used, and the episodic patients, in addition to being resistant to conventional medication, had longer cluster headache periods, exceeding the average time of previous cluster cycles. Our main analysis was of the time to pain-free, complete remission, and the length of pain-free time and complete remission. Results Clomiphene was used for 45-180 days. The average time to being pain-free was 15 days and cluster remission was up to 60 days. The average time between being pain-free until cluster remission was 26 days. Conclusions Clomiphene treatment was significantly efficient. It interrupted chronicity in all patients, suggesting the capability of changing the pattern of attacks. It proved to be safe and well tolerated.